GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hebei Changshan Biochemical Pharmaceutical Co Ltd (SZSE:300255) » Definitions » Debt-to-Equity

Hebei Changshan Biochemical Pharmaceutical Co (SZSE:300255) Debt-to-Equity : 1.60 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hebei Changshan Biochemical Pharmaceutical Co Debt-to-Equity?

Hebei Changshan Biochemical Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥2,062.3 Mil. Hebei Changshan Biochemical Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥449.7 Mil. Hebei Changshan Biochemical Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ¥1,566.0 Mil. Hebei Changshan Biochemical Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2025 was 1.60.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SZSE:300255' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.22   Med: 0.42   Max: 1.6
Current: 1.6

During the past 13 years, the highest Debt-to-Equity Ratio of Hebei Changshan Biochemical Pharmaceutical Co was 1.60. The lowest was 0.22. And the median was 0.42.

SZSE:300255's Debt-to-Equity is ranked worse than
92.08% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs SZSE:300255: 1.60

Hebei Changshan Biochemical Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hebei Changshan Biochemical Pharmaceutical Co Debt-to-Equity Chart

Hebei Changshan Biochemical Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.55 0.80 1.28 1.59

Hebei Changshan Biochemical Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.30 1.29 1.59 1.60

Competitive Comparison of Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity

For the Biotechnology subindustry, Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity falls into.


;
;

Hebei Changshan Biochemical Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hebei Changshan Biochemical Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Hebei Changshan Biochemical Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hebei Changshan Biochemical Pharmaceutical Co  (SZSE:300255) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Hebei Changshan Biochemical Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hebei Changshan Biochemical Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hebei Changshan Biochemical Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
North of Yinchuan Street, Zhengding New District, Hebei, Shijiazhuang, CHN, 050800
Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.
Executives
Li Zhi Hua Executives
Wang Jun Executives
Ding Jian Wen Directors, executives
Huang Guo Sheng Executives
Gao Shu Hua Directors, executives
Chen Xi Director
Cai Hao Executives
Ji Sheng Li Directors, executives
Li Xin Securities Affairs Representative
Zhang Wei Secretary Dong
Liu Jian Executives
Zhang Zhi Ying Executives
Guo Yan Xing Supervisors

Hebei Changshan Biochemical Pharmaceutical Co Headlines

No Headlines